These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29136952)

  • 1. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
    Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
    Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
    Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
    Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
    Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
    Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.
    Giordano G; Febbraro A; Tomaselli E; Sarnicola ML; Parcesepe P; Parente D; Forte N; Fabozzi A; Remo A; Bonetti A; Manfrin E; Ghasemi S; Ceccarelli M; Cerulo L; Bazzoni F; Pancione M
    J Exp Clin Cancer Res; 2015 Oct; 34():108. PubMed ID: 26427914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells.
    Li Y; Huang S; Li Y; Zhang W; He K; Zhao M; Lin H; Li D; Zhang H; Zheng Z; Huang C
    Tumour Biol; 2016 Oct; 37(10):14205-14215. PubMed ID: 27553025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.
    Kumar SS; Tomita Y; Wrin J; Bruhn M; Swalling A; Mohammed M; Price TJ; Hardingham JE
    Clin Transl Oncol; 2017 Jun; 19(6):718-726. PubMed ID: 28005260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
    Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA and mRNA profiling in cetuximab-resistant colorectal cancer cells by RNA sequencing analysis.
    Jing C; Ma R; Cao H; Wang Z; Liu S; Chen D; Wu Y; Zhang J; Wu J
    Cancer Med; 2019 Apr; 8(4):1641-1651. PubMed ID: 30848094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.
    Mlcochova J; Faltejskova-Vychytilova P; Ferracin M; Zagatti B; Radova L; Svoboda M; Nemecek R; John S; Kiss I; Vyzula R; Negrini M; Slaby O
    Oncotarget; 2015 Nov; 6(36):38695-704. PubMed ID: 26497852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.
    Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H
    Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab.
    Li Z; Chen Y; Ren WU; Hu S; Tan Z; Wang Y; Chen Y; Zhang J; Wu J; Li T; Xu J; Ying X
    Cancer Genomics Proteomics; 2019; 16(3):207-219. PubMed ID: 31018951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
    Okada Y; Kimura T; Nakagawa T; Okamoto K; Fukuya A; Goji T; Fujimoto S; Sogabe M; Miyamoto H; Muguruma N; Tsuji Y; Okahisa T; Takayama T
    Mol Cancer Res; 2017 Oct; 15(10):1445-1454. PubMed ID: 28698359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.